This study is looking at the effects of Panobinostat, an investigational treatment, on cancer
cells in patients who have Hodgkin lymphoma (a cancer of the immune system with specific
Hodgkin/Reed Sternberg Cells), T-cell lymphoma (a cancer of the immune system with too many T
lymphocytes), chronic lymphocytic leukemia or prolymphocytic leukaemia (immune system with
too many lymphocytes in the blood stream), lymphoplasmacytic lymphoma (immune system with too
many plasma cells or B lymphocytes) or myeloma (a cancer of plasma cells).
Panobinostat is a new drug which has led to disease improvement in some patients with Hodgkin
lymphoma, certain types of T-cell lymphoma, myeloma and some B cell lymphomas. Not all
patients benefit from panobinostat.
The researchers wish to look at the effects of panobinostat on cancer cells. The aim of this
project is find out which patients or diseases are likely to respond to treatment with
panobinostat in the future and to see if there are particular features of the patient or of
the cancer that affects the likelihood of the way individuals respond to panobinostat.
Panobinostat is an oral medication (taken by mouth) that effects the way cancer cells and in
normal cells make proteins. Panobinostat has been used in several clinical trials around the
world. The largest trials generally have fewer than 200 patients and are in Hodgkin lymphoma,
cutaneous T-cell lymphoma, and myeloma where between one in five and one in three patients
have significant improvement in their disease.
Researchers will look at samples of tumour before treatment and during treatment. This will
be one of the first studies to look at how cancer cells change following treatment with this
drug. It is unusual because it requires repeated biopsies of the participant's tumour.
Panobinostat is considered an experimental (or investigational) drug and not approved by any
regulatory authority (such as the Food and Drug Administration, FDA in the USA or by the
Therapeutics Goods and Administration, TGA, in Australia) to treat any type of cancer.
Therefore, Panobinostat is not approved to treat patients who have been diagnosed with
refractory or relapsed cancer.
A total of 30 patients with one of the diseases listed above will be enrolled at Peter
MacCallum Cancer Centre.
It is expected it will take about 2 to 3 years to recruit 30 patients and that on average
patients will take part for six to eighteen months. This time could be shorter or longer
depending on how well the treatment works in each individual. While the trial will take up to
4 years to complete, the science studies may take longer.